EU Pharmaceuticals : ADA wrap (AZN/NOVO/ROG/ZEAL)

Research evidence excerpt

EU Pharmaceuticals : ADA wrap (AZN/NOVO/ROG/ZEAL)

Deutsche Bank

Research

Emerging Europe Industry Date

Europe 10 June 2026

EU Pharmaceuticals

Pharmaceuticals Breaking News

Pharmaceuticals

ADA wrap (AZN/NOVO/ROG/ZEAL)

Emmanuel Papadakis, Ph.D., CFA

Summary takes Research Analyst

After providing our thoughts on the initial abstracts (EU Pharma: ADA abstract +44-20-754-18522

takes and thoughts into the conference (AZN/NOVO/ROG/ZEAL) (29/05/26)) and

Niall Alexander

individual takes on calls from Novo (NOVO: ADA call takes + MASH feedback Research Analyst

(08/06/26)), Roche (ROG: ADA call feedback: the alchemy exercise is still in full +44-20-754-12185

swing (+ZEAL)* (09/06/26)) and AZN (AZN: Belated ADA call feedback and

Henrietta Boeg

elecoglipron takes (+Novo) (10/06/26)) investor calls from the conference this

Research Associate

past weekend we provide a detailed wrap of all the key data presented this past

+44-20-754-10119

weekend at the annual key diabesity conference ADA in one place, along with some

upfront summary takes below. Kate Farrelly

Brief details

Shashindra Seresinhe n For Novo we covered our key views in our investor call feedback note:

here we provide a comprehensive review of the REIMAGINE1-3 updates, Research Associate

including a detailed summary of exactly what was new at the conference

(i.e. incremental details on RI1/2 and first details on RI3), along with the Supun Ukwatta

same exercise for zenagamtide/amycretin (though we remind this was Research Associate

confined to additional details on the previously headlined P2 diabetes data).

n For ROG/ZEAL – we detail first full (we remind ZEAL did host a call on the

headline but didn’t provide full details) petrelentide ZUPREME-1 data and